-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The incidence of stomach cancer (GC) is the fifth highest (5.7 per cent) in global cancer incidence and the third highest in cancer-related mortality (8.2 per cent).
in several classification systems for stomach cancer, Lauren classifies GC as intestinal and diffuse stomach cancer according to tissue form.
Cancer Genome Atlas Research Network recently proposed classing GC into four subtypes: (1) microsatellitor instability (MSI);(3) at the EB virus-positive (Epstein-Barr virus, EBV);(2) level;
these classifications indicate that stomach adenocarcinoma has a variety of molecular backgrounds and can lead to a variety of clinical manifestations.
immunotherapy has become a promising strategy for treating all types of cancer.
little is known about its role in stomach cancer.
the study was designed to assess the prognostic significance of immune cell scores (CD3 plus, CD8 plus), tumor immune escape (PD-L1, PD-1) and immune tolerance (Clever-1).
The five-year survival rate of patients with gastric adenocarcinoma classified according to the immune cell score was 122 patients who had a routine D2 gastric cancer excision after excluding ebvirus-positive (n-4) and microsatellite instability (n-6).
Immune Cell Score (ICS) based on CD3 plus and CD8 plus, as well as the expression levels of PD-L1, PD-1 and Cever-1.
the differences in patient survival rates through Cox regression models, mainly five-year survival rates.
poor prognostic studies of patients with high PD-L1, PD-1, and Lever-1 expressions showed a 5-year total survival rate of 43.4%.
ICS corresponds to a higher total survival rate than low ICS.
in high ICS groups, patients with high expression levels of PD-L1, PD-1, and Cever-1 had poor prognosis.
, the study revealed that high ICS corresponds to higher survival rates in patients.
in the high ICS group, patients with high levels of expression of PD-L1, PD-1 and Cever-1 had poor prognosis, highlighting the importance of immune escape and immune tolerance in stomach cancer.
.
